scholarly journals High Remission Rate with Infliximab and Plant-Based Diet as First-Line (IPF) Therapy for Severe Ulcerative Colitis: Single-Group Trial

2020 ◽  
Vol 24 (5) ◽  
Author(s):  
Mitsuro Chiba
Keyword(s):  
Ulcerative Colitis ◽  
Remission Rate ◽  
Single Group ◽  
First Line ◽  
Severe Ulcerative Colitis ◽  
Group Trial

scholarly journals Sa1029 – Cost-Effectiveness of First-Line Biologics for the Management of Moderate-To-Severe Ulcerative Colitis

2019 ◽  
Vol 156 (6) ◽  
pp. S-260-S-261
Author(s):  
Candace L. Beilman ◽  
Richard N. Fedorak ◽  
Brendan P. Halloran
Keyword(s):  
Ulcerative Colitis ◽  
Cost Effectiveness ◽  
First Line ◽  
Severe Ulcerative Colitis

scholarly journals Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Hiromichi Shimizu ◽  
Toshimitsu Fujii ◽  
Kenji Kinoshita ◽  
Ami Kawamoto ◽  
Shuji Hibiya ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Cohort Study ◽  
Primary Outcome ◽  
Remission Rate ◽  
Survival Rates ◽  
Efficacy And Safety ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Severe Ulcerative Colitis ◽  
Intravenous Corticosteroid

Abstract Background Intravenous corticosteroid is the mainstay for managing acute severe ulcerative colitis, but one-third of patients do not respond to intravenous corticosteroid. Tacrolimus, a salvage therapy before colectomy, is usually orally administered, though its bioavailability is low compared intravenous administration. The efficacy of intravenous tacrolimus has not been widely studied. Aim To determine the efficacy and safety of intravenous tacrolimus for the treatment of acute severe ulcerative colitis. Methods Eighty-seven hospitalized acute severe ulcerative colitis patients were enrolled for a prospective cohort study between 2009 and 2017. Sixty-five patients received intravenous tacrolimus and 22 received oral tacrolimus. The primary outcome was the achievement of clinical remission within 2 weeks. Relapse and colectomy incidence and adverse events were assessed at 24 weeks. Results Response rates of both treatments exceeded 50% but were not significantly different. The remission rate was higher in intravenous tacrolimus compared with oral tacrolimus. At 24 weeks, oral and intravenous tacrolimus showed similar relapse-free survival rates; however, colectomy-free survival rates were higher in intravenous tacrolimus compared with oral tacrolimus. Conclusions Patients receiving intravenous tacrolimus achieved superior remission and colectomy-free survival rates compared with patients receiving oral tacrolimus. Safety was similar between the two treatments.

Appendiceal Orifice Inflammation in Severe Ulcerative Colitis and Its Resolution With Infliximab and Plant-based Diet as First-line Therapy

2021 ◽  
Author(s):  
Mitsuro Chiba ◽  
Hajime Ishii ◽  
Masato Sageshima ◽  
Akira Iwabuchi
Keyword(s):  
Ulcerative Colitis ◽  
Induction Therapy ◽  
First Line ◽  
Severe Ulcerative Colitis ◽  
Distal Ulcerative Colitis ◽  
First Line Therapy ◽  
Line Therapy

Lay Summary Appendiceal orifice inflammation, which is often observed in mild or moderate distal ulcerative colitis, was observed in a case of severe UC. Appendiceal orifice inflammation resolved after new induction therapy for severe UC: infliximab and a plant-based diet as first-line therapy.

Sign in / Sign up

Export Citation Format

Share Document